Analysts expect Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) to report $-0.13 EPS on February, 11.After having $-0.18 EPS previously, Cyclacel Pharmaceuticals, Inc.’s analysts see -27.78 % EPS growth. The stock decreased 1.20% or $0.01 during the last trading session, reaching $0.82. About 33,286 shares traded. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has declined 54.10% since February 10, 2018 and is downtrending. It has underperformed by 54.10% the SP500.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company has market cap of $10.25 million. The company’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. It currently has negative earnings.